Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Immunisation

Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients

Bone Marrow Transplantation volume 27, pages 79–84 (2001)Cite this article

Abstract

Forty-four adult BMT recipients transplanted from an HLA-identical sibling donor were randomized to receive meningococcal polysaccharide (Men PS) vaccine either 8 (early group; 22 patients) or 20 (late group; 22 patients) months after BMT. The geometric mean concentrations (GMC) of antibodies to serogroup A Neisseria meningitidis (Men A) and serogroup C Neisseria meningitidis (Men C), determined by an EIA method, decreased during the first 6 months after BMT but remained at a stable level thereafter. Before vaccination the GMCs of anti-Men A were 1.53 μg/ml and 1.61 μg/ml, but 1 month after vaccination they were significantly higher, 3.46 μg/ml and 6.39 μg/ml, in the early and late groups. The GMCs of anti-Men C increased from 0.37 μg/ml and 0.44 μg/ml before vaccination to 3.31 μg/ml and 4.62 μg/ml at 1 month after vaccination in the early and late groups, respectively. By 6 months after vaccination the GMCs of Men antibodies had decreased to levels of about 50% of those measured at 1 month after vaccination. Two-fold responses to Men A PS were seen in 52% and 74% and to Men C PS in 76% and 89% of the BMT recipients in the early and late groups, respectively. Chronic GVHD had no influence on the vaccination response. In the present study, Men PS vaccine induced good and equal antibody responses to Men A and Men C PSs in allogeneic BMT recipients regardless of timing after BMT. Vaccination against Neisseria meningitidis should be considered, especially in the event of travelling or military service ⩾8 months after BMT. Bone Marrow Transplantation (2001) 27, 79–84.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Jafari HS, Perkins BA . Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 1997 46: 1–10

    Google Scholar 

  2. Ramsay M, Kaczmarski E, Rush M et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales Commun Dis Rep CDR Rev 1997 7: R49-R54

    Google Scholar 

  3. Connolly M, Noah N, on behalf of the European Meningitis Surveillance Group . Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993–6 Epidemiol Infect 1999 122: 41–49

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ramsay M, Collins M, Rush M, Kaczmarski E . The epidemiology of meningococcal disease in England and Wales, 1996 and 1997 Eurosurveillance 1997 2: 74–76

    Article  PubMed  Google Scholar 

  5. Infectious diseases in Finland 1998 Annual report National Public Health Institute: Helsinki, Finland 1999

  6. Gold R, Lepow ML, Goldschneider I et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants J Clin Invest 1975 56: 1536–1547

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gold R, Lepow ML, Goldschneider I et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children J Infect Dis 1979 140: 690–697

    Article  CAS  PubMed  Google Scholar 

  8. Peltola H, Safary A, Käyhty H et al. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-Acetyl-Negative and O-Acetyl-Positive group C polysaccharides Pediatrics 1985 76: 91–96

    CAS  PubMed  Google Scholar 

  9. King WJ, MacDonald NE, Wells G et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children J Pediatr 1996 128: 196–202

    Article  CAS  PubMed  Google Scholar 

  10. Witherspoon RP, Lum LG, Storb R . Immunologic reconstitution after human marrow grafting Semin Hematol 1984 21: 2–10

    CAS  PubMed  Google Scholar 

  11. Lum LG . The kinetics of immune reconstitution after human marrow transplantation Blood 1987 69: 369–380

    CAS  PubMed  Google Scholar 

  12. Lum LG . Immune recovery after bone marrow transplantation Hematol Oncol Clin North Am 1990 4: 659–675

    Article  CAS  PubMed  Google Scholar 

  13. Storek J, Saxon A . Reconstitution of B cell immunity following bone marrow transplantation Bone Marrow Transplant 1992 9: 395–408

    CAS  PubMed  Google Scholar 

  14. Winston DJ, Ho WG, Schiffman G et al. Pneumococcal vaccination of recipients of bone marrow transplants Arch Intern Med 1983 143: 1735–1737

    Article  CAS  PubMed  Google Scholar 

  15. Giebink GS, Warkentin PI, Ramsay NKC, Kersey JH . Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine J Infect Dis 1986 154: 590–596

    Article  CAS  PubMed  Google Scholar 

  16. Barra A, Cordonnier C, Preziosi M-P et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients J Infect Dis 1992 166: 1021–1028

    Article  CAS  PubMed  Google Scholar 

  17. Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K . Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation Clin Exp Immunol 1992 88: 512–519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hammarström V, Pauksen K, Azinge J et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction Support Care Cancer 1993 1: 195–199

    Article  PubMed  Google Scholar 

  19. Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients Transplantation 1994 57: 677–684

    Article  CAS  PubMed  Google Scholar 

  20. Molrine DC, Guinan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation Blood 1996 87: 3012–3018

    CAS  PubMed  Google Scholar 

  21. Parkkali T, Käyhty H, Ruutu T et al. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT Bone Marrow Transplant 1996 18: 961–967

    CAS  PubMed  Google Scholar 

  22. Engelhard D, Cordonnier C, Shaw PJ et al. Invasive pneumococcal infection following PBSCT and BMT – an EBMT survey Bone Marrow Transplant 1999 23: (Suppl. 1) S114 (Abstr. 368)

    Google Scholar 

  23. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 1994 84: 2036–2043

    CAS  PubMed  Google Scholar 

  24. Tallman MS, Rowlings PA, Milone G et al. Role of postremission chemotherapy in recipients of HLA-identical sibling transplants for acute myelogenous leukemia in first remission Blood 1997 90: (Suppl. 1) 254a (Abstr. 1117)

    Google Scholar 

  25. Ruutu T, Volin L, Parkkali T et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study Blood 2000 96: 2391–2398

    CAS  PubMed  Google Scholar 

  26. Heinonen H, Volin L, Uutela A et al. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation Ann Hematol (in press)

  27. Platonov AE, Beloborodov VB, Pavlova LI et al. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine Clin Exp Immunol 1995 100: 32–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Arakere G, Frasch CE . Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers Infect Immun 1991 59: 4349–4356

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Holder PK, Maslanka SE, Pais LB et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992 Clin Diagn Lab Immunol 1995 2: 132–137

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Peltola H, Mäkelä PH, Käyhty H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age New Engl J Med 1977 297: 686–691

    Article  CAS  PubMed  Google Scholar 

  31. Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1995 15: 455–460

    CAS  PubMed  Google Scholar 

  32. Ljungman P . Immunization of transplant recipients Bone Marrow Transplant 1999 23: 635–636

    Article  CAS  PubMed  Google Scholar 

  33. Quinti I, Velardi A, Le Moli S et al. Antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation J Clin Immunol 1990 10: 160–166

    Article  CAS  PubMed  Google Scholar 

  34. Witherspoon RP, Storb R, Ochs HD et al. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment Blood 1981 58: 360–368

    CAS  PubMed  Google Scholar 

  35. Käyhty H, Karanko V, Peltola H et al. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children J Infect Dis 1980 142: 861–868

    Article  PubMed  Google Scholar 

  36. Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children: a randomized controlled trial JAMA 1996 275: 1499–1503

    Article  CAS  PubMed  Google Scholar 

  37. MacDonald NE, Halperin SA, Law BJ et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial JAMA 1998 280: 1685–1689

    Article  CAS  PubMed  Google Scholar 

  38. Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory J Infect Dis 1999 179: 1569–1572

    Article  CAS  PubMed  Google Scholar 

  39. Brandt BL, Artenstein MS . Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide J Infect Dis 1975 131: (Suppl.) S69-S72

    Article  Google Scholar 

  40. Zangwill KM, Stout RW, Carlone GM et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel J Infect Dis 1994 169: 847–852

    Article  CAS  PubMed  Google Scholar 

  41. Committee on Infectious Diseases, American Academy of Pediatrics Infectious Diseases and Immunization Committee, Canadian Paediatric Society . Meningococcal disease prevention and control strategies for practice-based physicians Pediatrics 1996 97: 404–411

    Google Scholar 

  42. Kalhs P, Panzer S, Kletter K et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease Ann Intern Med 1988 109: 461–464

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Haematology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

    T Parkkali, T Ruutu & L Volin

  2. National Public Health Institute, Helsinki, Finland

    H Käyhty, H Lehtonen, J Eskola & P Ruutu

Authors
  1. T Parkkali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Käyhty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Lehtonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Eskola
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parkkali, T., Käyhty, H., Lehtonen, H. et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant 27, 79–84 (2001). https://doi.org/10.1038/sj.bmt.1702742

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702742

Keywords

This article is cited by

Search

Advanced search

Quick links